SAB BIOTHERAPEUTICS INC

Sab Biotherapeutics shares plunge –‑2.08% as market doubts rise, thin liquidity, and a shaky clinical pipeline put investors on guard.

Sab Biotherapeutics stock climbs 2.77% as investors eye upcoming clinical data and strategic moves, highlighting opportunities in the clinical‑stage biotech space.

Sab Biotherapeutics (SABS) rebounds after a 23% dip, breaking its 200‑day SMA—key for biotech buyers. Explore its clinical pipeline, market resilience, and partnership prospects for a potential upside.